Evidence map›Paper›PMID 24619956›Full record

ArticleMolecular carcinogenesis2015

Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells.

Inga Koneczny, Axel Schulenburg, Xenia Hudec, Martin Knöfler, Klaus Holzmann, Gary Piazza, Robert Reynolds, Peter Valent, Brigitte Marian

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. FGF/FGFR signaling in health and disease.Signal transduction and targeted therapy · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer.Journal of cancer research and clinical oncology · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Inga Koneczny *Medical University Vienna, Department of Medicine 1, Division of Bone Marrow Transplantation.
Axel Schulenburg *Medical University Vienna Institute of Cancer Research.
Xenia HudecMedical University Vienna, Department of Medicine 1, Division of Bone Marrow Transplantation.
Martin KnöflerMedical University Vienna Department of Obstetrics and Gynaecology.
Klaus HolzmannMedical University Vienna, Department of Medicine 1, Division of Bone Marrow Transplantation.
Gary PiazzaMitchell Cancer Institute, University of South Alabama.
Robert ReynoldsDepartment of Medicinal Chemistry, Drug Discovery Division, Southern Research Institute.
Peter ValentMedical University Vienna Division of Hematology.
Brigitte MarianMedical University Vienna, Department of Medicine 1, Division of Bone Marrow Transplantation.
Comprehensive Cancer Center Vienna · ATMedical University of Vienna · ATSouthern Research Institute · USUSA Mitchell Cancer Institute · US

Funding

Selective anti-cancer activity of sulindac derivatives on KRAS mutant colon tumor cells by inducing ROSR01CA131378 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2008 to 2019
$5.2M
Development of a novel sulindac amide for colorectal cancer chemopreventionR01CA148817 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2010 to 2015
$2.4M
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer ChemopreventionR01CA155638 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2012 to 2017
$2.3M
NCI NIH HHS 1R01CA131378NCI NIH HHS 1R01CA148817NCI NIH HHS R01 CA131378NCI NIH HHS R01 CA148817NCI NIH HHS R01 CA155638
6 · The paper itself

Abstract

Expansion of a stem-like subpopulation with increased growth and survival potential is thought to drive colorectal tumor growth and progression. We investigated a CD44-positive (CD44((+))) subpopulation with extended growth and survival capacity in the human colon adenoma cell line LT97. This subpopulation expressed elevated levels of fibroblast growth factor 18 (FGF18) and fibroblast growth factor receptor FGFR3-IIIc. Expression levels of the FGFR3-IIIb, which does not bind FGF18, were similar in CD44((+)) and CD44((-)). Addition of FGF18 to the medium or its overexpression from an adenoviral vector increased the colony formation capacity of CD44((+)) threefold, and stimulated phosphorylation of ERK and GSK3β in both total LT97 populations and CD44((+)) cells. FGFR3 signaling blockade by expression of a dominant-negative FGFR3-IIIc mutant led to inhibition of both colony formation and down-stream signaling in the CD44((+)) cells. CD44((-)) cells did not respond. Blockade of the wnt-pathway by a dominant-negative Tcf4-mutant inhibited FGFR3 activation in LT97 cells as well as in HT29 colorectal cancer cells. The chemical wnt-inhibitor sulindac sulfide amide inhibited expression of FGF18 and FGFR3-IIIc and led to inhibition of receptor activation to less than 30% of control treated cells, both in LT97 and HT29 cultures. Our results demonstrate that an FGF18/FGFR3-IIIc autocrine growth and survival loop is up-regulated in a wnt-dependent manner and drives tumor cell growth in a subpopulation of colon adenoma cells. This subpopulation can be regarded as a precursor of colon cancer development and can be targeted for CRC-prevention by blocking either wnt- or FGFR3-signaling.

Indexed as

Signal TransductionAdenomaAntineoplastic AgentsColonColorectal NeoplasmsFibroblast Growth FactorsHumansHyaluronan ReceptorsReceptor, Fibroblast Growth Factor, Type 3RectumSulindacWnt ProteinsWnt Signaling PathwayAntineoplastic Agentsfibroblast growth factor 18Fibroblast Growth FactorsHyaluronan ReceptorsReceptor, Fibroblast Growth Factor, Type 3Sulindacsulindac sulfide amideWnt ProteinsCD44colon adenomaFGF

Identifiers

PMID24619956
PMCPMC4162857
OpenAlexW2161167579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.